1. Neurology. 2020 Dec 15;95(24):e3288-e3302. doi: 10.1212/WNL.0000000000010914. 
Epub 2020 Sep 17.

C9orf72, age at onset, and ancestry help discriminate behavioral from language 
variants in FTLD cohorts.

Costa B(1), Manzoni C(2), Bernal-Quiros M(1), Kia DA(1), Aguilar M(1), Alvarez 
I(1), Alvarez V(1), Andreassen O(1), Anfossi M(1), Bagnoli S(1), Benussi L(1), 
Bernardi L(1), Binetti G(1), Blackburn D(1), Boada M(1), Borroni B(1), Bowns 
L(1), Bråthen G(1), Bruni AC(1), Chiang HH(1), Clarimon J(1), Colville S(1), 
Conidi ME(1), Cope TE(1), Cruchaga C(1), Cupidi C(1), Di Battista ME(1), 
Diehl-Schmid J(1), Diez-Fairen M(1), Dols-Icardo O(1), Durante E(1), Flisar 
D(1), Frangipane F(1), Galimberti D(1), Gallo M(1), Gallucci M(1), Ghidoni R(1), 
Graff C(1), Grafman JH(1), Grossman M(1), Hardy J(1), Hernández I(1), Holloway 
GJT(1), Huey ED(1), Illán-Gala I(1), Karydas A(1), Khoshnood B(1), Kramberger 
MG(1), Kristiansen M(1), Lewis PA(1), Lleó A(1), Madhan GK(1), Maletta R(1), 
Maver A(1), Menendez-Gonzalez M(1), Milan G(1), Miller B(1), Mol MO(1), Momeni 
P(1), Moreno-Grau S(1), Morris CM(1), Nacmias B(1), Nilsson C(1), Novelli V(1), 
Öijerstedt L(1), Padovani A(1), Pal S(1), Panchbhaya Y(1), Pastor P(1), Peterlin 
B(1), Piaceri I(1), Pickering-Brown S(1), Pijnenburg YAL(1), Puca AA(1), Rainero 
I(1), Rendina A(1), Richardson AMT(1), Rogaeva E(1), Rogelj B(1), Rollinson 
S(1), Rossi G(1), Rossmeier C(1), Rowe JB(1), Rubino E(1), Ruiz A(1), 
Sanchez-Valle R(1), Sando SB(1), Santillo AF(1), Saxon J(1), Scarpini E(1), 
Serpente M(1), Smirne N(1), Sorbi S(1), Suh E(1), Tagliavini F(1), Thompson 
JC(1), Trojanowski JQ(1), Van Deerlin VM(1), Van der Zee J(1), Van Broeckhoven 
C(1), van Rooij J(1), Van Swieten JC(1), Veronesi A(1), Vitale E(1), Waldö 
ML(1), Woodward C(1), Yokoyama J(1), Escott-Price V(1), Polke JM(1), Ferrari 
R(2); International FTD-Genetics Consortium.

Author information:
(1)From the Institute of Neurology (B.C., D.A.K., J.H., P.A.L., R.F.), School of 
Pharmacy (C.M.), and UCL Movement Disorders Centre (J.H.), University College 
London; School of Pharmacy (C.M., P.A.L.), University of Reading, Whiteknights; 
Neurogenetics Laboratory (M.B.-Q., C.W., J.M.P.), National Hospital for 
Neurology and Neurosurgery, London, UK; Aptima Clinic (Miquel Aguilar), 
Terrassa; Memory Disorders Unit, Department of Neurology (I.A., M.D.-F., P.P.), 
University Hospital Mutua de Terrassa, Barcelona; Hospital Universitario Central 
de Asturias (V.A., M.M.-G.), Oviedo, Spain; NORMENT (O.A.), Institute of 
Clinical Medicine, University of Oslo, Norway; Regional Neurogenetic Centre 
(Maria Anfossi, Livia Bernardi, A.C.B., M.E.C., Chiara Cupidi, F.F., Maura 
Gallo, R.M., N.S.), ASPCZ, Lamezia Terme; Department of Neuroscience, 
Psychology, Drug Research and Child Health (S.B., B.N., I.P., S.S.), University 
of Florence; Molecular Markers Laboratory (Luisa Benussi, Giuliano Binetti, 
R.G.), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, 
Italy; Sheffield Institute for Translational Neuroscience (SITraN), Department 
of Neuroscience (D.B.), University of Sheffield, UK; Research Center and Memory 
Clinic (M.B., I.H., S.M.-G., Agustín Ruiz), Fundació ACE, Institut Català de 
Neurociències Aplicades, Universitat Internacional de Catalunya (UIC), 
Barcelona, Spain; Centre for Neurodegenerative Disorders (B.B., A.P.), 
Department of Clinical and Experimental Sciences, University of Brescia, Italy; 
Department of Clinical Neurosciences (Lucy Bowns, T.E.C., J.B.R.), Cambridge 
University, UK; Department of Neurology (Geir Bråthen, S.B.S.), University 
Hospital of Trondheim, Norway; Dept NVS, Division of Neurogeriatrics (H.-H.C., 
C.G., B.K., L.Ö.), Karolinska Institutet, Bioclinicum Solna, Sweden; Department 
of Neurology (J.C., O.D.-I., I.I.-G., A.L.), IIB Sant Pau, Hospital de la Santa 
Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Anne Rowling 
Regenerative Neurology Clinic (S.C., G.J.T.H., S.P.) and Centre for Clinical 
Brain Sciences (S.P.), University of Edinburgh, UK; NeuroGenomics and 
Informatics, Department of Psychiatry (Carlos Cruchaga), Washington University, 
St. Louis, MO; Cognitive Impairment Center (M.E.D.B., Maurizio Gallucci) and 
Immunohematology and Transfusional Medicine Service (E.D., A.V.), Local Health 
Authority n.2 Marca Trevigiana, Treviso, Italy; Department of Psychiatry and 
Psychotherapy (J.D.-S., C.R.), School of Medicine, Technical University of 
Munich, Germany; Department of Neurology (D.F., M.G.K.) and Clinical Institute 
of Medical Genetics (A.M., B.P.), University Medical Center Ljubljana, Slovenia; 
Dino Ferrari Center (D.G., Elio Scarpini, M.S.), University of Milan, Italy; 
Cognitive Neuroscience Lab, Think and Speak Lab (J.H.G.), Shirley Ryan Ability 
Lab, Chicago, IL; Department of Pathology and Laboratory Medicine (Murray 
Grossman, EunRan Suh, J.Q.T., V.M.V.D.), Center for Neurodegenerative Diseases, 
Perelman School of Medicine at the University of Pennsylvania, Philadelphia; UCL 
Dementia Research Institute (J.H.), London; Reta Lila Weston Institute (J.H.), 
UCL Queen Square Institute of Neurology, UK; Institute for Advanced Study 
(J.H.), The Hong Kong University of Science and Technology, China; Royal 
Edinburgh Hospital (G.J.T.H.), UK; Taub Institute for Research on Alzheimer's 
Disease and the Aging Brain (E.D.H.), Columbia University, New York, NY; 
Department of Neurology, Memory and Aging Center (A.K., B.M., J.Y.), University 
of California, San Francisco; UCL Genomics (M.K., G.K.M., Y.P.), UCL Great 
Ormond Street Institute of Child Health, London, UK; Geriatric Center Frullone 
ASL Napoli 1 Centro (G.M.), Napoli, Italy; Department of Neurology (M.O.M., 
J.v.R., J.C.V.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Rona 
Holdings (P.M.), Silicon Valley, CA; Newcastle Brain Tissue Resource, Institute 
of Neuroscience (C.M.M.), Newcastle University, Campus for Ageing and Vitality, 
Newcastle upon Tyne, UK; Department of Neurology (C.N.), Skåne University 
Hospital, Malmö, Sweden; Fondazione Policlinico Universitario A. Gemelli IRCCS 
(V.N.), Rome, Italy; Division of Neuroscience & Experimental Psychology 
(S.P.-B., A.M.T.R., S.R., J.C.T.), University of Manchester, UK; Amsterdam 
University Medical Center (Y.A.L.P.), VU University Medical Center, the 
Netherlands; Cardiovascular Research Unit (A.A.P.), IRCCS Multimedica, Milan; 
Neurology I, Department of Neuroscience (I.R., Elisa Rubino), University of 
Torino; NeurOMICS laboratory (G.M., Antonella Rendina, E.V.), Institute of 
Biochemistry and Cell Biology (IBBC), CNR Napoli, Italy; Manchester Centre for 
Clinical Neurosciences (A.M.T.R., J.S., J.C.T.), Salford Royal NHS Trust, 
Manchester, UK; Tanz Centre for Research in Neurodegenerative Diseases 
(Ekaterina Rogaeva), University of Toronto, Canada; Department of Biotechnology 
(B.R.), Jožef Stefan Institute, Ljubljana, Slovenia; Division of Neurology V and 
Neuropathology (G.R., F.T.), Fondazione IRCCS Istituto Neurologico Carlo Besta, 
Milan, Italy; Alzheimer's Disease and Other Cognitive Disorders Unit (R.S.-V.), 
Hospital Clínic of Barcelona, Spain; Clinical Memory Research Unit, Department 
of Clinical Sciences Malmö (C.N., A.F.S.), and Division of Clinical Sciences 
Helsingborg, Department of Clinical Sciences Lund (M.L.W.), Lund University, 
Sweden; Neurodegenerative Brain Diseases Group (J.V.d.Z., C.V.B.), Center for 
Molecular Neurology, VIB, Antwerp, Belgium; Medical Research Council Centre for 
Neuropsychiatric Genetics and Genomics (V.E.-P.), Division of Psychological 
Medicine and Clinical Neurosciences and Dementia Research Institute, Cardiff 
University, UK; Instituto de Investigación Sanitaria del Principado de Asturias 
(V.A.), Oviedo, Asturias; Fundació per la Recerca Biomèdica i Social Mútua 
Terrassa (I.A., M.D.-F., P.P.), Barcelona; Centro de Investigación Biomédica en 
Red de Enfermedades Neurodegenerativas (CIBERNED) (M.B., J.C., O.D.-I., I.H., 
I.I.-G., A.L., S.M.-G., Agustín Ruiz), Instituto de Salud Carlos III, Madrid, 
Spain; MRC Cognition and Brain Sciences Unit (Lucy Bowns, T.E.C., J.B.R.), 
Cambridge University, UK; Department of Neuromedicine and Movement Science (Geir 
Bråthen, S.B.S.), Norwegian University of Science and Technology, Trondheim, 
Norway; Unit for Hereditary Dementias (H.-H.C., C.G., B.K., L.Ö.), Theme Aging, 
Karolinska University Hospital, Solna, Sweden; Medical Faculty (D.F., M.G.K.), 
University of Ljubljana, Slovenia; Fondazione IRCCS Ca'Granda (D.G., Elio 
Scarpini, M.S.), Ospedale Policlinico, Milan, Italy; Penn Center for 
Frontotemporal Degeneration (Murray Grossman), Philadelphia, PA; Universidad de 
Oviedo (M.M.-G.), Asturias, Spain; IRCCS Fondazione Don Carlo Gnocchi (B.N., 
S.S.), Florence; Istituto di Medicina Genomica (V.N.), Università Cattolica del 
sacro Cuore, Rome, Italy; Amsterdam Neuroscience (Y.A.L.P.), the Netherlands; 
Department of Medicine and Surgery (A.A.P.), University of Salerno, Baronissi 
(SA), Italy; Faculty of Chemistry and Chemical Technology (B.R.), University of 
Ljubljana, Slovenia; Institud d'Investigacions Biomèdiques August Pi i Sunyer 
(R.S.-V.), Barcelona, Spain; Department of Biomedical Sciences (J.V.d.Z., 
C.V.B.), University of Antwerp, Belgium; and Department of Comparative 
Biomedical Sciences (P.A.L.), The Royal Veterinary College, London, UK.
(2)From the Institute of Neurology (B.C., D.A.K., J.H., P.A.L., R.F.), School of 
Pharmacy (C.M.), and UCL Movement Disorders Centre (J.H.), University College 
London; School of Pharmacy (C.M., P.A.L.), University of Reading, Whiteknights; 
Neurogenetics Laboratory (M.B.-Q., C.W., J.M.P.), National Hospital for 
Neurology and Neurosurgery, London, UK; Aptima Clinic (Miquel Aguilar), 
Terrassa; Memory Disorders Unit, Department of Neurology (I.A., M.D.-F., P.P.), 
University Hospital Mutua de Terrassa, Barcelona; Hospital Universitario Central 
de Asturias (V.A., M.M.-G.), Oviedo, Spain; NORMENT (O.A.), Institute of 
Clinical Medicine, University of Oslo, Norway; Regional Neurogenetic Centre 
(Maria Anfossi, Livia Bernardi, A.C.B., M.E.C., Chiara Cupidi, F.F., Maura 
Gallo, R.M., N.S.), ASPCZ, Lamezia Terme; Department of Neuroscience, 
Psychology, Drug Research and Child Health (S.B., B.N., I.P., S.S.), University 
of Florence; Molecular Markers Laboratory (Luisa Benussi, Giuliano Binetti, 
R.G.), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, 
Italy; Sheffield Institute for Translational Neuroscience (SITraN), Department 
of Neuroscience (D.B.), University of Sheffield, UK; Research Center and Memory 
Clinic (M.B., I.H., S.M.-G., Agustín Ruiz), Fundació ACE, Institut Català de 
Neurociències Aplicades, Universitat Internacional de Catalunya (UIC), 
Barcelona, Spain; Centre for Neurodegenerative Disorders (B.B., A.P.), 
Department of Clinical and Experimental Sciences, University of Brescia, Italy; 
Department of Clinical Neurosciences (Lucy Bowns, T.E.C., J.B.R.), Cambridge 
University, UK; Department of Neurology (Geir Bråthen, S.B.S.), University 
Hospital of Trondheim, Norway; Dept NVS, Division of Neurogeriatrics (H.-H.C., 
C.G., B.K., L.Ö.), Karolinska Institutet, Bioclinicum Solna, Sweden; Department 
of Neurology (J.C., O.D.-I., I.I.-G., A.L.), IIB Sant Pau, Hospital de la Santa 
Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Anne Rowling 
Regenerative Neurology Clinic (S.C., G.J.T.H., S.P.) and Centre for Clinical 
Brain Sciences (S.P.), University of Edinburgh, UK; NeuroGenomics and 
Informatics, Department of Psychiatry (Carlos Cruchaga), Washington University, 
St. Louis, MO; Cognitive Impairment Center (M.E.D.B., Maurizio Gallucci) and 
Immunohematology and Transfusional Medicine Service (E.D., A.V.), Local Health 
Authority n.2 Marca Trevigiana, Treviso, Italy; Department of Psychiatry and 
Psychotherapy (J.D.-S., C.R.), School of Medicine, Technical University of 
Munich, Germany; Department of Neurology (D.F., M.G.K.) and Clinical Institute 
of Medical Genetics (A.M., B.P.), University Medical Center Ljubljana, Slovenia; 
Dino Ferrari Center (D.G., Elio Scarpini, M.S.), University of Milan, Italy; 
Cognitive Neuroscience Lab, Think and Speak Lab (J.H.G.), Shirley Ryan Ability 
Lab, Chicago, IL; Department of Pathology and Laboratory Medicine (Murray 
Grossman, EunRan Suh, J.Q.T., V.M.V.D.), Center for Neurodegenerative Diseases, 
Perelman School of Medicine at the University of Pennsylvania, Philadelphia; UCL 
Dementia Research Institute (J.H.), London; Reta Lila Weston Institute (J.H.), 
UCL Queen Square Institute of Neurology, UK; Institute for Advanced Study 
(J.H.), The Hong Kong University of Science and Technology, China; Royal 
Edinburgh Hospital (G.J.T.H.), UK; Taub Institute for Research on Alzheimer's 
Disease and the Aging Brain (E.D.H.), Columbia University, New York, NY; 
Department of Neurology, Memory and Aging Center (A.K., B.M., J.Y.), University 
of California, San Francisco; UCL Genomics (M.K., G.K.M., Y.P.), UCL Great 
Ormond Street Institute of Child Health, London, UK; Geriatric Center Frullone 
ASL Napoli 1 Centro (G.M.), Napoli, Italy; Department of Neurology (M.O.M., 
J.v.R., J.C.V.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Rona 
Holdings (P.M.), Silicon Valley, CA; Newcastle Brain Tissue Resource, Institute 
of Neuroscience (C.M.M.), Newcastle University, Campus for Ageing and Vitality, 
Newcastle upon Tyne, UK; Department of Neurology (C.N.), Skåne University 
Hospital, Malmö, Sweden; Fondazione Policlinico Universitario A. Gemelli IRCCS 
(V.N.), Rome, Italy; Division of Neuroscience & Experimental Psychology 
(S.P.-B., A.M.T.R., S.R., J.C.T.), University of Manchester, UK; Amsterdam 
University Medical Center (Y.A.L.P.), VU University Medical Center, the 
Netherlands; Cardiovascular Research Unit (A.A.P.), IRCCS Multimedica, Milan; 
Neurology I, Department of Neuroscience (I.R., Elisa Rubino), University of 
Torino; NeurOMICS laboratory (G.M., Antonella Rendina, E.V.), Institute of 
Biochemistry and Cell Biology (IBBC), CNR Napoli, Italy; Manchester Centre for 
Clinical Neurosciences (A.M.T.R., J.S., J.C.T.), Salford Royal NHS Trust, 
Manchester, UK; Tanz Centre for Research in Neurodegenerative Diseases 
(Ekaterina Rogaeva), University of Toronto, Canada; Department of Biotechnology 
(B.R.), Jožef Stefan Institute, Ljubljana, Slovenia; Division of Neurology V and 
Neuropathology (G.R., F.T.), Fondazione IRCCS Istituto Neurologico Carlo Besta, 
Milan, Italy; Alzheimer's Disease and Other Cognitive Disorders Unit (R.S.-V.), 
Hospital Clínic of Barcelona, Spain; Clinical Memory Research Unit, Department 
of Clinical Sciences Malmö (C.N., A.F.S.), and Division of Clinical Sciences 
Helsingborg, Department of Clinical Sciences Lund (M.L.W.), Lund University, 
Sweden; Neurodegenerative Brain Diseases Group (J.V.d.Z., C.V.B.), Center for 
Molecular Neurology, VIB, Antwerp, Belgium; Medical Research Council Centre for 
Neuropsychiatric Genetics and Genomics (V.E.-P.), Division of Psychological 
Medicine and Clinical Neurosciences and Dementia Research Institute, Cardiff 
University, UK; Instituto de Investigación Sanitaria del Principado de Asturias 
(V.A.), Oviedo, Asturias; Fundació per la Recerca Biomèdica i Social Mútua 
Terrassa (I.A., M.D.-F., P.P.), Barcelona; Centro de Investigación Biomédica en 
Red de Enfermedades Neurodegenerativas (CIBERNED) (M.B., J.C., O.D.-I., I.H., 
I.I.-G., A.L., S.M.-G., Agustín Ruiz), Instituto de Salud Carlos III, Madrid, 
Spain; MRC Cognition and Brain Sciences Unit (Lucy Bowns, T.E.C., J.B.R.), 
Cambridge University, UK; Department of Neuromedicine and Movement Science (Geir 
Bråthen, S.B.S.), Norwegian University of Science and Technology, Trondheim, 
Norway; Unit for Hereditary Dementias (H.-H.C., C.G., B.K., L.Ö.), Theme Aging, 
Karolinska University Hospital, Solna, Sweden; Medical Faculty (D.F., M.G.K.), 
University of Ljubljana, Slovenia; Fondazione IRCCS Ca'Granda (D.G., Elio 
Scarpini, M.S.), Ospedale Policlinico, Milan, Italy; Penn Center for 
Frontotemporal Degeneration (Murray Grossman), Philadelphia, PA; Universidad de 
Oviedo (M.M.-G.), Asturias, Spain; IRCCS Fondazione Don Carlo Gnocchi (B.N., 
S.S.), Florence; Istituto di Medicina Genomica (V.N.), Università Cattolica del 
sacro Cuore, Rome, Italy; Amsterdam Neuroscience (Y.A.L.P.), the Netherlands; 
Department of Medicine and Surgery (A.A.P.), University of Salerno, Baronissi 
(SA), Italy; Faculty of Chemistry and Chemical Technology (B.R.), University of 
Ljubljana, Slovenia; Institud d'Investigacions Biomèdiques August Pi i Sunyer 
(R.S.-V.), Barcelona, Spain; Department of Biomedical Sciences (J.V.d.Z., 
C.V.B.), University of Antwerp, Belgium; and Department of Comparative 
Biomedical Sciences (P.A.L.), The Royal Veterinary College, London, UK. 
r.ferrari@ucl.ac.uk c.manzoni@ucl.ac.uk.

OBJECTIVE: We sought to characterize C9orf72 expansions in relation to genetic 
ancestry and age at onset (AAO) and to use these measures to discriminate the 
behavioral from the language variant syndrome in a large pan-European cohort of 
frontotemporal lobar degeneration (FTLD) cases.
METHODS: We evaluated expansions frequency in the entire cohort (n = 1,396; 
behavioral variant frontotemporal dementia [bvFTD] [n = 800], primary 
progressive aphasia [PPA] [n = 495], and FTLD-motor neuron disease [MND] [n = 
101]). We then focused on the bvFTD and PPA cases and tested for association 
between expansion status, syndromes, genetic ancestry, and AAO applying 
statistical tests comprising Fisher exact tests, analysis of variance with Tukey 
post hoc tests, and logistic and nonlinear mixed-effects model regressions.
RESULTS: We found C9orf72 pathogenic expansions in 4% of all cases (56/1,396). 
Expansion carriers differently distributed across syndromes: 12/101 FTLD-MND 
(11.9%), 40/800 bvFTD (5%), and 4/495 PPA (0.8%). While addressing population 
substructure through principal components analysis (PCA), we defined 2 patients 
groups with Central/Northern (n = 873) and Southern European (n = 523) ancestry. 
The proportion of expansion carriers was significantly higher in bvFTD compared 
to PPA (5% vs 0.8% [p = 2.17 × 10-5; odds ratio (OR) 6.4; confidence interval 
(CI) 2.31-24.99]), as well as in individuals with Central/Northern European 
compared to Southern European ancestry (4.4% vs 1.8% [p = 1.1 × 10-2; OR 2.5; CI 
1.17-5.99]). Pathogenic expansions and Central/Northern European ancestry 
independently and inversely correlated with AAO. Our prediction model (based on 
expansions status, genetic ancestry, and AAO) predicted a diagnosis of bvFTD 
with 64% accuracy.
CONCLUSIONS: Our results indicate correlation between pathogenic C9orf72 
expansions, AAO, PCA-based Central/Northern European ancestry, and a diagnosis 
of bvFTD, implying complex genetic risk architectures differently underpinning 
the behavioral and language variant syndromes.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on 
behalf of the American Academy of Neurology.

DOI: 10.1212/WNL.0000000000010914
PMCID: PMC7836664
PMID: 32943482 [Indexed for MEDLINE]